SCHEMBL2762229

SCHEMBL2762229

Cc1n[nH]cc1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630091 0.71
SCHEMBL152676 0.71
SCHEMBL28286560 0.71 KCNH2 (0.33)
SCHEMBL28180965 0.69
Hydrochloric Acid SCHEMBL8132392 0.69
SCHEMBL28286561 0.69
SCHEMBL28324841 0.69
Water SCHEMBL27506609 0.69
Hydrochloric Acid SCHEMBL22691784 0.69
Phosphine SCHEMBL28098732 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025245087-A1 HETEROCYCLIC COMPOUNDS AS PARG INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2025-11-27 WO disclosed
WO-2025111492-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. (US) 2025-05-30 WO disclosed
EP-4486444-A1 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS F. Hoffmann-La Roche AG (CH) 2025-01-08 EP disclosed
WO-2023165943-A1 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2023-09-07 WO disclosed
EP-3938050-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. (US) 2022-01-19 EP disclosed
WO-2020190754-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. (US) 2020-09-24 WO disclosed
WO-2020117877-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE AQUINNAH PHARMACEUTICALS, INC. (US) 2020-06-11 WO disclosed
EP-2922821-B1 S1P AND/OR ATX MODULATING AGENTS BIOGEN MA INC (US) 2019-07-31 EP disclosed
EP-2879673-B1 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (S1P) receptor and/or autotaxin (ATX) modulators for treating inflammatory and autoimmune disorders BIOGEN MA INC (US) 2018-07-25 EP disclosed
CN-105348266-B 3 chlorine N [3 (the base amino of the pyrimidine 2) phenyl] propionamides or its salt of substitution 阿斯利康(瑞典)有限公司 2018-04-10 CN disclosed
EP-1401826-A1 PYRAZOLE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-03-31 EP disclosed
US-6699887-B2 ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A PYRRAZOLE SULFIDE OR ETHER COMPOUND TO TREAT THE HUMAN IMMUNODEFICIENCY VIRUS INFECTION HOFFMANN-LA ROCHE INC. 2004-03-02 US disclosed
CN-1469865-A Pyrazole derivatives for the treatment of viral diseases - 2004-01-21 CN disclosed
EP-1326843-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. Hoffmann-La Roche AG (CH) 2003-07-16 EP disclosed
US-6538015-B1 Process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds of formula I are inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is HOFFMANN-LA ROCHE INC. 2003-03-25 US disclosed
US-20030018197-A1 Anti-HIV pyrazole derivatives HOFFMANN-LA ROCHE INC. 2003-01-23 US disclosed
WO-2002100853-A1 PYRAZOLE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2002-12-19 WO disclosed
WO-2002030907-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2002-04-18 WO disclosed
EP-0043917-A2 Esters of N-acylated-N-methyl-0-pyrazol(4)yl-carbamic acids, process for their preparation and their application as biocides BAYER AG (DE) 1982-01-20 EP disclosed
EP-0012344-A1 O-Pyrazol-4-yl-O-ethyl-S-n-propyl-(thiono)thiol-phosphoric-acid esters, process for preparing them and their use as pesticides BAYER AG (DE) 1980-06-25 EP disclosed